GIP can enhance insulin secretion in the postprandial state and increase the anabolic effect of insulin in adipose tissue, thus promoting adipogenesis and preadipocyte differentiation [31, 32], while GLP-1RA can control blood glucose and lower body weight, reduce postprandial lipoprotein secretion, decrease systemic tissue inflammation, and help improve hepatic lipid metabolism disorders [33–35], which has some beneficial effects on NAFLD. This evidence concerns the gene GIP and metabolic dysfunction-associated steatotic liver disease.